TRENTON, N.J. (AP) - Federal regulators have approved the first nonopioid treatment to ease withdrawal symptoms from quitting addictive opioids.
The U.S. Food and Drug Administration expedited approval of Lucemyra (luc-eh-MEER'-eh) to help combat the U.S. opioid epidemic.
The tablet was approved Wednesday to treat adults for up to two weeks for common withdrawal symptoms like vomiting, diarrhea, muscle pain and agitation. It is not an addiction treatment but can be part of a longer-term plan.
People going through detox are usually given opioid medicine like methadone, which eases the cravings without an intense high. Fear of withdrawal discourages some people from quitting.
The FDA is requiring drugmaker US WorldMeds of Louisville, Kentucky, to conduct safety studies in teens and newborns of opioid-addicted mothers and for possible longer-term use in people tapering off opioids.
(Copyright 2018 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.)
5/16/2018 5:21:32 PM (GMT -5:00)
- FDA approves 1st nonopioid drug to ease withdrawal symptoms
- FDA approves drug for treating postpartum depression
- FDA approves first postpartum depression drug
- FDA approves preventive migraine treatment
- FDA investigating 127 reports of seizures, neurological symptoms related to vaping
- The FDA has five weeks till money runs out for approving new drugs
- Showers Easing Through This Week
- Heat eases and rain increases
- FDA approves technology to analyze nutrients in breast milk
- FDA approves medication to help with postpartum depression